Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting

Randomized, triple-blind crossover study in adult inpatient psychiatry units comparing a single nebulized dose of ketamine (1.5 mg/kg) with an active midazolam placebo (0.03 mg/kg); participants complete 4 or 5 visits depending on randomised arm.

Dosing visits are in-person with a minimum 2-hour post-dose observation including regular vital sign monitoring; the intervention is administered via nebuliser as an adjunct to concomitant medications and therapies.